TransThera Sciences (Nanjing). Inc. (2617) AI Stock Analysis

5 Followers

TransThera Sciences (Nanjing). Inc.

(HKEX:2617)

Select Model

Rating:43Neutral

Price Target:HKD 7.50▼(-5.96% Downside)

Action:reiterated

Date:09/22/26

The overall score is constrained mainly by very weak financial performance, with no meaningful revenue, ongoing sizable losses, and heavy cash burn that erodes the equity base despite a low-leverage balance sheet. Short-term technicals offer some support through moderate positive momentum, but this is tempered by a much weaker longer-term trend and high volatility. The valuation remains speculative, with a negative P/E and no dividend, so the investment case depends heavily on future clinical and commercialization success rather than current financial strength.

Positive Factors

Very low leverageMinimal debt reduces refinancing and interest-rate exposure, preserving financial flexibility while the company funds drug discovery and clinical development. This conservative capital structure provides more resilience than a highly leveraged model if operating losses or funding needs remain elevated.

Negative Factors

Pre-revenue operating modelThe absence of reported revenue leaves the company dependent on future clinical and commercial success rather than an established operating franchise. Without current sales, near-term funding capacity and business-model validation remain limited, increasing reliance on continued development progress.

TransThera Sciences (Nanjing). Inc. (2617) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 3.11B
Dividend Yield: ―
Average Volume (3M): 4.65M
Price to Earnings (P/E): -6.6
Beta (1Y): 2.70
Revenue Growth: ―
EPS Growth: -13.19%
Country: Hong Kong
Employees: 132
Sector: General
Sector Strength: 55
Industry: Biotechnology

TransThera Sciences (Nanjing). Inc. Business Overview & Revenue Model

Company Description

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a...

TransThera Sciences (Nanjing). Inc. Financial Statement Overview

Summary

Financial performance is weak overall: TransThera is still pre-revenue with no sales in 2024–2025, deeply negative profitability, and heavy, persistent operating and free cash outflows. This is partially offset by a relatively strong, low-debt balance sheet with a sizable but shrinking equity cushion that provides some resilience while R&D-intensive development continues.

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2020
Income Statement
Total Revenue	34.97M	0	0	1.18M	124.00K	61.76M
Gross Profit	30.68M	0	0	1.18M	124.00K	0
EBITDA	-267.59M	-290.82M	-267.97M	-413.42M	8.55M	-39.27M
Net Income	-268.29M	-295.96M	-274.61M	-344.12M	-250.04M	-80.72M
Balance Sheet
Total Assets	987.24M	545.91M	629.60M	887.09M	1.35B	344.94M
Cash, Cash Equivalents and Short-Term Investments	925.22M	489.14M	572.53M	838.17M	1.11B	279.34M
Total Debt	5.61M	1.65M	4.37M	4.81M	3.04M	490.74M
Total Liabilities	109.26M	129.53M	104.57M	103.91M	111.04M	578.87M
Stockholders Equity	877.99M	416.38M	525.03M	783.18M	1.24B	-233.94M
Cash Flow
Free Cash Flow	-144.55M	-253.68M	-271.95M	-331.12M	-244.00M	-76.61M
Operating Cash Flow	-144.47M	-253.51M	-271.18M	-319.33M	-241.94M	-66.68M
Investing Cash Flow	108.03M	-68.00M	348.42M	-186.94M	26.98M	-195.84M
Financing Cash Flow	1.55M	169.00M	-4.87M	15.76M	240.45M	311.48M

TransThera Sciences (Nanjing). Inc. Technical Analysis

Technical Analysis SentimentNegative

Last Price7.97

Price Trends

50DMA9.40Negative

100DMA9.99Negative

200DMA35.13Negative

Market Momentum

MACD-0.45Negative

RSI36.93Neutral

STOCH39.16Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2617, the sentiment is Negative. The current price of 7.97 is below the 20-day moving average (MA) of 8.48, below the 50-day MA of 9.40, and below the 200-day MA of 35.13, indicating a bearish trend. The MACD of -0.45 indicates Negative momentum. The RSI at 36.93 is Neutral, neither overbought nor oversold. The STOCH value of 39.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2617.

TransThera Sciences (Nanjing). Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

HK:2617 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:9995	66Neutral	HKD 55.77B	8.43	105.60%	―	292.84%	―
HK:1548	65Neutral	HKD 78.95B	-13.59	-16.23%	―	53.48%	-120.02%
HK:2696	65Neutral	HKD 27.20B	26.74	20.41%	―	32.63%	8.74%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
HK:9688	50Neutral	HKD 25.55B	-14.81	-31.11%	―	0.28%	8.30%
HK:2617	43Neutral	HKD 2.56B	-6.59	-40.84%	―	―	-13.19%
HK:1877	41Neutral	HKD 31.66B	-73.54	-7.23%	―	35.82%	54.40%

* General Sector Average

Performance Comparison

HK:2617 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:2617	TransThera Sciences (Nanjing). Inc.	7.97	-196.22	-96.09%
HK:1548	Genscript Biotech Corporation	31.84	14.55	84.15%
HK:9688	Zai Lab Ltd	21.02	3.91	22.85%
HK:9995	RemeGen Co. Ltd. Class H	69.35	-16.10	-18.84%
HK:1877	Shanghai Junshi Biosciences Co., Ltd. Class H	15.74	-10.10	-39.09%
HK:2696	Shanghai Henlius Biotech, Inc. Class H	49.98	-17.12	-25.51%

TransThera Sciences (Nanjing). Inc. Corporate Events

TransThera Wins HKEX Nod for H-Share Full Circulation Conversion

Nov 1, 2026

TransThera Sciences (Nanjing), Inc. has received approval from the Hong Kong Stock Exchange to list 44,971,128 converted H shares, which will be transformed from the same number of previously unlisted shares. These converted shares, held by 10 partic...

TransThera Sciences Advances Full Circulation Plan for H Shares After CSRC Filing

Oct 26, 2026

TransThera Sciences (Nanjing), Inc., a PRC-based biopharmaceutical company listed on the Hong Kong Stock Exchange, is pursuing capital market optimization by converting a portion of its domestic shares into H shares to improve liquidity. The company’...

TransThera launches national rollout of first-in-China cholangiocarcinoma drug Yochanra

Oct 22, 2026

TransThera Sciences (Nanjing), Inc. has begun nationwide commercialisation of its core oncology drug Yochanra (tinengotinib tablets) in China after securing conditional marketing approval for adults with unresectable advanced or metastatic cholangioc...

TransThera’s Tinengotinib Secures CSCO Guideline Placement for Advanced Biliary Tract Cancers

Sep 18, 2026

TransThera Sciences has announced that its self-developed multi-target kinase inhibitor YOCHANRA (tinengotinib) has been included as a Class II, Class 2A recommendation in the 2026 Chinese Society of Clinical Oncology guidelines for the diagnosis and...

TransThera Starts Phase II Trial of Tinengotinib Combo in Resistant Prostate Cancer

Sep 18, 2026

TransThera Sciences (Nanjing), Inc., a China-based biopharma company specializing in innovative oncology drugs, is developing tinengotinib, a multi-target kinase inhibitor aimed at solid tumors such as cholangiocarcinoma and prostate cancer. With exi...

TransThera Sciences Narrows Interim Loss as Revenue Emerges Amid Rising R&D Spend

Aug 26, 2026

TransThera Sciences (Nanjing), Inc. reported its unaudited interim results for the six months ended 30 June 2026, posting revenue of RMB35.46 million versus no revenue a year earlier and a gross profit of the same amount as no cost of sales was recor...

TransThera Sciences Sets Board Meeting to Review Interim Results and Potential Dividend

Aug 14, 2026

TransThera Sciences (Nanjing), Inc. has scheduled a board meeting for 26 August 2026 to review and approve its unaudited consolidated interim results for the six months ended 30 June 2026. The board will also consider the declaration and payment of a...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 22, 2026

TransThera Sciences (Nanjing). Inc. AI Stock Analysis